Background: MUSIC-OS is a prospective, observational study which investigates the burden of gastrointestinal (GI) events and association with treatment (Tx) satisfaction, adherence, healthcare resource use, and quality of life among osteoporotic (OP) women in Canada, France, Italy, the Netherlands, Sweden and the UK. The objective of our study was to examine the association of GI events on OP Tx satisfaction among osteoporotic women.
Methods: Osteoporotic women >=50 years treated with OP medication were enrolled in the study during routine physician visits. Women diagnosed with Parkinsons disease, neuromuscular disease, Pagets disease, malignant neoplasm or treated with any injectable OP medication at enrolment were excluded. Women treated for OP were asked to complete the OP Patient Satisfaction Questionnaire (OPSAT-Q) regarding their OP Tx satisfaction at baseline (BL) and 6 and 12 months post-BL. Both new users (same OP Tx for <90 days) and experienced users (same OP Tx for >90 days) were included. Multivariate regression analysis estimated the association between GI events and OP Tx satisfaction after controlling for demographics and clinical characteristics.
Results: 2943 women with mean age of 69.5 years were enrolled. Women who reported a GI event at six months after BL, but did not report any GI event at BL, had significantly lower OPSAT-Q scores compared with women who had not reported a GI event at 6 months after BL (LS Means difference: -3.97, p=0.0004, 95% CI: -6.16, -1.78). New users with GI events at 6 months after BL had lower OPSAT-Q scores compared to those without GI events (LS means difference: -6.11, p=0.0062, 95% CI:-10.49,-1.74). Experienced users with GI events at 6 months (213 of 700, 30.4%) also had lower Tx satisfaction than those without GI events (LS means difference: -3.61, p=0.0051, 95% CI:-6.14, -1.08).
Conclusion: Results demonstrate that experience of new GI events may lower OP Tx satisfaction among osteoporotic women.
Disclosure: Employees of Merck & Co., Inc. have contributed to the design and implementation of this study. This study is fully funded by Merck & Co., Inc.